Small Molecules in Oncology and Hematology

ISBN-13: 9783030129484 / Angielski / Twarda / 2019

Uwe Martens

Opis

This two-volume set describes the most recent developments in the use of small molecules for targeted therapy in hematology and oncology. In each book a wide range of small molecules are covered. Those of most relevance in hematology include tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib, while, in addition to tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors and cell cycle and NTRK interacting agents are of particular interest in oncology. For each molecule, chemical structure, mechanism of action, drug targets, and drug interactions are described. The results of preclinical studies and clinical trials are reviewed, with presentation of the latest information on treatment applications. The extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. In presenting key advances in the field, this impressive set will be of interest and value for both researchers and clinicians.

O autorze

Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.